Literature DB >> 27529534

Faulty splicing and cytoskeleton abnormalities in Huntington's disease.

Marta Fernández-Nogales1,2, María Santos-Galindo1,2, Ivó H Hernández1,2, Jorge R Cabrera3, José J Lucas1,2.   

Abstract

Huntington's disease (HD) is caused by a CAG-repeat encoding a polyglutamine (polyQ) tract in the huntingtin protein. There is plenty of evidence of polyQ-driven toxicity. However, CAG repeat RNA-driven alteration of splicing has recently been proposed in analogy to CUG-repeat diseases. Here we review the reported alteration of the CAG-repeat associated splicing factor SRSF6 in brains of HD patients and mouse models and how this correlates with altered splicing of, at least, two microtubule-associated proteins in HD, namely MAPT (tau) and MAP2. Regarding tau, altered splicing of exon 10 has been reported, along with increased levels and 4R/3R-tau ratio and detection of tau in a new nuclear rod-shaped histopathological hallmark termed tau nuclear rod (TNR) or tau nuclear indentation (TNI). These findings, together with an attenuation of HD phenotype in R6/1 mice with tau deficiency and subsequent studies showing increased phosphorylation in mouse models and increased levels in CSF of patients, has led to proposing HD as a tauopathy. Regarding MAP2, an increase in its juvenile form and a decrease in total MAP2 together with redistribution from dendrites to soma is observed in HD patients, which may contribute to the dendritic atrophy in HD. Furthermore, MAP2 positive structures filling nuclear indentations have occasionally been found and co-localized with tau. Therefore, altered MAP function with imbalance in tau/MAP2 content could contribute to HD striatal atrophy and dysfunction. Besides, TNIs might be indicative of such MAP abnormalities. TNIs are also found in early pathology Alzheimer's disease and in tauopathy mice over-expressing mutant 4R-tau. This indicates that tau alteration is sufficient for TNI detection, which becomes a marker of increased total tau and/or altered 4R/3R-tau ratio and reporter of pathology-associated nuclear indentations. Altogether, these recent studies suggest that correcting the SRSF6-driven missplicing and/or microtubule-associated imbalance might be of therapeutic value in HD.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  Huntington's disease; MAP2; SRSF6; TNI (tau-immunopositive nuclear indentation); TNR (tau nuclear rod); splicing; tau; tauopathy

Mesh:

Substances:

Year:  2016        PMID: 27529534     DOI: 10.1111/bpa.12430

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  13 in total

1.  Radiosynthesis and Evaluation of [11C]HD-800, a High Affinity Brain Penetrant PET Tracer for Imaging Microtubules.

Authors:  Kiran Kumar Solingapuram Sai; Jaya Prabhakaran; Gayathri Ramanathan; Stephanie Rideout; Christopher Whitlow; Akiva Mintz; J John Mann; J S Dileep Kumar
Journal:  ACS Med Chem Lett       Date:  2018-04-30       Impact factor: 4.345

2.  Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Authors:  Joshua D Crapser; Joseph Ochaba; Neelakshi Soni; Jack C Reidling; Leslie M Thompson; Kim N Green
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

Review 3.  Alternative splicing isoforms in health and disease.

Authors:  Hyoung Kyu Kim; Michael Huy Cuong Pham; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Pflugers Arch       Date:  2018-03-13       Impact factor: 3.657

Review 4.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

Review 5.  Tau Toxicity in Neurodegeneration.

Authors:  Shu-Yu Liang; Zuo-Teng Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2022-03-31       Impact factor: 5.682

Review 6.  Adrenomedullin, a Novel Target for Neurodegenerative Diseases.

Authors:  Hilda Ferrero; Ignacio M Larrayoz; Francisco J Gil-Bea; Alfredo Martínez; María J Ramírez
Journal:  Mol Neurobiol       Date:  2018-03-29       Impact factor: 5.590

7.  Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental Phenotypes.

Authors:  An Verheyen; Annick Diels; Joke Reumers; Kirsten Van Hoorde; Ilse Van den Wyngaert; Constantin van Outryve d'Ydewalle; An De Bondt; Jacobine Kuijlaars; Louis De Muynck; Ronald De Hoogt; Alexis Bretteville; Steffen Jaensch; Arjan Buist; Alfredo Cabrera-Socorro; Selina Wray; Andreas Ebneth; Peter Roevens; Ines Royaux; Pieter J Peeters
Journal:  Stem Cell Reports       Date:  2018-07-26       Impact factor: 7.765

8.  Intranasal Administration of miR-146a Agomir Rescued the Pathological Process and Cognitive Impairment in an AD Mouse Model.

Authors:  Hui Mai; Weihao Fan; Yan Wang; Yujie Cai; Xiaohui Li; Feng Chen; Xiongjin Chen; Jingqi Yang; Pei Tang; Huiyi Chen; Ting Zou; Tingting Hong; Conghua Wan; Bin Zhao; Lili Cui
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-10       Impact factor: 8.886

9.  Alternative splicing and cancer: a systematic review.

Authors:  Yuanjiao Zhang; Jinjun Qian; Chunyan Gu; Ye Yang
Journal:  Signal Transduct Target Ther       Date:  2021-02-24

Review 10.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.